Timothy Alexander

Omega Flex Profit Falls 39% as Housing Weakness Hits Sales EXTON, PA — Omega Flex, Inc. (NASDAQ: OFLX) reported a 38.5% drop in first-half net income as weaker housing activity reduced sales volumes and h […]

Toppoint Narrows Loss as Import, Metal Mix Lifts Margins NORTH WALES, PA — Toppoint Holdings Inc. (NYSE American: TOPP) narrowed its second-quarter net loss by 80% as revenue rose 17% and a shift toward h […]

ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (NASDAQ: AVBP) is approaching a pivotal Phase 3 readout for its lead lung cancer drug while advancing t […]

NBME Doubles Medical School Scholarships Amid Physician Shortage PHILADELPHIA, PA — NBME doubled the number of awards in its medical school scholarship program for the 2026-2027 cycle, granting 20 students $10,000 e […]

Exyn Builds Defense Advisory Board to Scale Military Autonomy PHILADELPHIA, PA — Exyn Technologies (NASDAQ: EXYN, EXYNW) formed a Defense Advisory Board and named former Pentagon official and Green Beret Andrew K […]

Aprea Expands Cancer Trial as APR-1051 Shows Early Activity DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) is expanding its Phase 1 trial of experimental cancer drug APR-1051 after reporting early s […]

Madrigal Adds J&J R&D Chief to Board as MASH Push Expands CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) appointed Johnson & Johnson research executive John C. Reed, M.D., Ph.D., to its b […]

Arbutus Plans $230 Million Share Buyback After Moderna Deal WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) plans to return up to approximately $230 million to shareholders after receiving $178.4 m […]

Mineralys Builds $661 Million War Chest Ahead of FDA Decision RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) ended the second quarter with $661.4 million in cash, cash equivalents and investments after r […]

Inhibikase Loss Widens as Phase 3 PAH Trial Expands WILMINGTON, DE— Inhibikase Therapeutics, Inc. (Nasdaq: IKT) nearly doubled its second-quarter net loss as spending increased on its Phase 3 pulmonary a […]

Vishay Cuts Capacitor Footprint 40% for Industrial Designs MALVERN, PA — Vishay Intertechnology, Inc. (NYSE: VSH) introduced a surface-mount series of Y1 safety capacitors that requires up to 40% less board s […]

ICYMI: A. Duie Pyle Extends Logistics Award Streak to 37 Years WEST CHESTER, PA — A. Duie Pyle earned recognition across four transportation and logistics categories in Logistics Management’s 2026 Quest for Qua […]

HHM Hotels Adds 11 Properties in Wurzak Management Deal PHILADELPHIA, PA — HHM Hotels is adding 11 properties managed by Wurzak Hotel Group to its portfolio, expanding the Philadelphia-based hotel o […]

Enviri Loss Widens on Rail Exit as EBITDA Improves PHILADELPHIA, PA — Enviri Corporation (NYSE: NVRI) posted a $297 million second-quarter loss from continuing operations as charges tied to its exit f […]

Angeion Extends Inc. 5000 Run as Legal Platform Expands PHILADELPHIA, PA — Angeion Group ranked No. 1,589 on the 2026 Inc. 5000, marking its fourth consecutive appearance as the Philadelphia-based legal a […]

Jenner’s Pond Opens Tech Series on AI, Aging and Care WEST GROVE, PA — Simpson is opening a technology-focused speaker series at its Jenner’s Pond senior living community in West Grove this month, bri […]

2X Revenue Jumps 264%, Extending Inc. 5000 Streak MALVERN, PA — 2X posted 264% revenue growth over three years to rank No. 1,330 on the 2026 Inc. 5000, extending the Malvern company’s run on the r […]

Prelude Cuts Quarterly Loss as Breast Cancer Trial Nears WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) narrowed its second-quarter loss by more than half and cut research spending as the p […]

Enviri Exits Rail Contracts, Takes $208 Million Balance-Sheet Hit PHILADELPHIA, PA — Enviri Corporation (NYSE: NVRI) has ended work on two troubled European rail-equipment contracts, triggering an approximately $75 m […]

Orchestra BioMed Loss Widens as Pivotal Trials Advance NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) widened its second-quarter loss by 23% as spending increased on two pivotal c […]